PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus

Inclusion Criteria: * Patient is willing and able to give informed consent for participation in the trial. * Male or Female, aged 18 years or above. * Type I Diabetics patients with end stage chronic renal failure * Recipient of kidney and pancreas-transplant * At least one of the two transplants are functioning at time of PK profile measurements : a patient with early pancreatic graft failure due to thrombosis may be included if the kidney is well functioning * Standard immunosuppressive therapy has been started post-operatively, in accordance with local policy, including tacrolimus. * In the Investigator's opinion, is able and willing to comply with all trial requirements. * Patients with social security. Exclusion Criteria: The participant may not enter the trial if ANY of the following apply: * Patient is inappropriate for standard immunosuppressive therapy. * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patients at risk because of participation in the trial, or may influence the result of the trial, or the patient's ability to participate in the trial. * Concomitant therapy with drugs potentially interfering with tacrolimus pharmacokinetics, especially those interfering with CYP3A4 (see 4.4 section in tacrolimus / ENVARSUS® summary of product characteristics). * Loss of the pancreatic graft due to immunological causes * Pregnant or breast-feeding women and female patient with potential childbearing refusing c…